Cart
sales@molnova.com
Indirubin-3-monoxime
CAS No. 667463-82-3
Indirubin-3-monoxime ( —— )
Catalog No. M24681 CAS No. 667463-82-3
Indirubin-3-monoxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 87 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 260 | In Stock |
|
| 50MG | 402 | In Stock |
|
| 100MG | 593 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIndirubin-3-monoxime
-
NoteResearch use only, not for human use.
-
Brief DescriptionIndirubin-3-monoxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
-
DescriptionIndirubin-3-monoxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
Recptorcdk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number667463-82-3
-
Formula Weight277.3
-
Molecular FormulaC16H11N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc([nH]c1c2cccc1)c2-c([nH]c1c2cccc1)c2N=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dera A A , Rajagopalan P , Fayi M A , et al. Indirubin-3-monoxime and thymoquinone exhibit synergistic efficacy as therapeutic combination in in-vitro and in-vivo models of Lung cancer[J]. Archives of Pharmacal Research, 2020, 43(10).
molnova catalog
related products
-
DprE1-IN-1
DprE1-IN-1 is a potent inhibitor of DprE1 and PDE6.
-
BQU57
BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth.
-
THZ-1
A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.
